Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)

China flag China · Delayed Price · Currency is CNY
36.26
-0.01 (-0.03%)
Apr 29, 2026, 3:00 PM CST
18.26%
Market Cap 5.77B
Revenue (ttm) 917.99M
Net Income (ttm) 168.68M
Shares Out 159.01M
EPS (ttm) 1.06
PE Ratio 34.22
Forward PE n/a
Dividend 0.60 (1.65%)
Ex-Dividend Date Jun 9, 2025
Volume 2,035,100
Average Volume 3,079,517
Open 35.98
Previous Close 36.27
Day's Range 35.35 - 36.65
52-Week Range 28.13 - 67.98
Beta 0.60
RSI 44.07
Earnings Date Apr 23, 2026

About SHA:603590

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 668
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603590
Full Company Profile

Financial Performance

In 2025, SHA:603590's revenue was 915.12 million, an increase of 10.87% compared to the previous year's 825.40 million. Earnings were 165.97 million, an increase of 293.13%.

Financial Statements

News

There is no news available yet.